Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Generic Pharma

STADA Arzneimittel AG

+ Add to Watchlist

STDAF:US

36.4000 USD 2.2501 6.59%

As of 20:10:00 ET on 04/15/2015.

Snapshot for STADA Arzneimittel AG (STDAF)

Open: 36.4000 Day's Range: 36.4000 - 36.4000 Volume: 137
Previous Close: 34.1499 52wk Range: 30.2000 - 46.4500 1-Yr Rtn: -

Stock Chart for STDAF

No chart data available.
  • STDAF:US 36.4000
  • 1D
  • 1M
  • 1Y
34.1499
Interactive STDAF Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for STDAF

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 12.1142
Relative P/E vs. SPX -
Earnings Per Share (EUR) (ttm) -
Est. EPS (EUR) (12/2015) 2.7640
Est. PEG Ratio 1.7992
Market Cap (M USD) 2,215.17
Shares Outstanding (M) 60.86
30 Day Average Volume 448
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield 1.93%
Cash Dividend (EUR) 0.6600
Dividend Ex-Date 06/04/2015
5 Year Dividend Growth 4.19%
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for STDAF

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for STDAF

Stada Arzneimittel AG manufactures pharmaceuticals. The Company produces generics (products whose patents have expired), brand-name products, and cancer therapy and other special pharmaceuticals. Stada avoids cost-intensive research on active ingredients and concentrates on multi-source products. The Company markets its products worldwide.

Hartmut RetzlaffChairman-Mgmt BoardHelmut KraftCFO/Member-Mgmt Board
Matthias WiedenfelsChief Business Develop-Mgmt BdMarkus MetzgerVP:Investor Relations
More Company Profile & Key Executives for STDAF

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil